Compare

FOXO4-DRI vs Selank

Side-by-side observational reports from PeptIQ users. This compares self-reported patterns — not clinical head-to-head trials.

Last reviewed . By the PeptIQ team.

Observational reporting only — not medical advice. Does not recommend doses, protocols, or treatments.
XRedditFacebook

FOXO4-DRI

28 community reports

Overall experience

From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Favorable 97% · Mixed 3% · Unfavorable overall 0%

Most reported benefits

Benefits users selected when logging a favorable or mixed check-in.

Recovery
178
Energy
178

Self-reported dose per injection

Median bucket: 2+ mg · Most common: 2+ mg

Reports span 1 to ≥ 2 mg (open-ended top bucket)

1–2 mg
58
2+ mg
120

Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.

How repeat users are trending

Among repeat reporters, 88% said they felt similar to their last entry, 12% more positive, and 0% more negative.

Overall, repeat reporters leaned more positive than their previous entry.

Median gap between entries: 194 days · Based on 26 repeat reporters

Selank

57 community reports

Overall experience

From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Favorable 3% · Mixed 97% · Unfavorable overall 0%

Most reported benefits

Benefits users selected when logging a favorable or mixed check-in.

Mood
184
Recovery
184

Most logged side effects

Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Injection site irritation
94
Fatigue
85

Self-reported dose per injection

Median bucket: 0.2–0.4 mg · Most common: 0.2–0.4 mg

Reports span 0.1 to ≥ 5 mg (open-ended top bucket)

0.1–0.2 mg
3
0.2–0.4 mg
96
0.4–0.6 mg
76
0.6–1 mg
5
1–2 mg
2
5+ mg
2

Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.

How repeat users are trending

Among repeat reporters, 86% said they felt similar to their last entry, 14% more positive, and 0% more negative.

Overall, repeat reporters leaned more positive than their previous entry.

Median gap between entries: 54 days · Based on 35 repeat reporters

Sources (9)

Published sources linked on the FOXO4-DRI and Selank wiki pages.

  1. PubMed

    Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging (FOXO4-DRI)

    Baar MP, Brandt RMC, Putavet DA, et al. Cell. 2017

    Source
    Wiki study page →

  2. PubMed

    Eliminating Senescent Cells Can Promote Pulmonary Hypertension Development and Progression

    Born E, Lipskaia L, Breau M, et al. Circulation. 2023

    Source
    Wiki study page →

  3. PubMed

    Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging

    Baar MP, Brandt RMC, Putavet DA, et al. Cell. 2017

    Source
    Wiki study page →

  4. PubMed

    Selank and short peptides regulate expression of inflammatory genes

    Ershov FI, Uchakin PN, Ershova OV. Bull Exp Biol Med. 2017

    Source
    Wiki study page →

  5. PubMed

    Selank, a tuftsin analogue, demonstrates anxiolytic activity

    Seredenin SB, Kozlovskaya MM. Bull Exp Biol Med. 2008

    Source
    Wiki study page →

  8. PubMed

    Functional Connectomic Approach to Studying Selank and Semax Effects

    Panikratova YR, Lebedeva IS, Sokolov OY, et al. Doklady biological sciences : proceedings of the Academy of Sciences of the USSR, Biological sciences sections. 2020

    Source
    Wiki study page →

  9. PubMed

    Selank, a Peptide Analog of Tuftsin, Attenuates Aversive Signs of Morphine Withdrawal in Rats

    Konstantinopolsky MA, Chernyakova IV, Kolik LG. Bulletin of experimental biology and medicine. 2022

    Source
    Wiki study page →

Explore other peptides